About Reapplix
Reapplix is a company based in Rudersdal (Denmark) founded in 2008 by Rasmus Lundquist and Niels Holm. Reapplix has raised $52.36 million across 9 funding rounds from investors including Accelerace, Novo Holdings and Danmarks Eksport- og Investeringsfond. The company has 10 employees as of February 29, 2024. Reapplix offers products and services including 3C Patch System. Reapplix operates in a competitive market with competitors including Organogenesis, Siren, Sofregen, BioTissue and Encellin, among others.
- Headquarter Rudersdal, Denmark
- Employees 10 as on 29 Feb, 2024
- Founders Rasmus Lundquist, Niels Holm
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Reapplix A/S
-
Annual Revenue
$255.86 K (USD)120as on Dec 31, 2021
-
Net Profit
-$4.99 M (USD)11as on Dec 31, 2021
-
EBITDA
-$5.27 M (USD)11as on Dec 31, 2021
-
Total Equity Funding
$52.36 M (USD)
in 9 rounds
-
Latest Funding Round
$22.73 M (USD), Series B
Jul 07, 2020
-
Investors
Accelerace
& 8 more
-
Employee Count
10
as on Feb 29, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Reapplix
Reapplix offers a comprehensive portfolio of products and services, including 3C Patch System.
Creates patches from patient blood to accelerate diabetic foot ulcer healing.
People of Reapplix
Unlock access to complete
Funding Insights of Reapplix
Reapplix has successfully raised a total of $52.36M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $22.73 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Reapplix
Reapplix has secured backing from 9 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Accelerace, Novo Holdings and Danmarks Eksport- og Investeringsfond.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
Provision of financing, loans, equity, and insurance for Danish export and investment activities.
|
Locked | Locked | Locked | |
|
Venture capital firm backing Nordic tech startups from seed to Series A with investments in Consumer, Deep Tech, and related sectors.
|
Locked | Locked | Locked |
Investor details for Reapplix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Reapplix
Investment portfolio details for Reapplix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Reapplix
Detailed financials for Reapplix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Reapplix Comparisons
Peer comparison for Reapplix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Reapplix
Reapplix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Organogenesis, Siren, Sofregen, BioTissue and Encellin, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Regenerative therapies for wound care are developed and commercialized.
|
|
| Locked | Locked | Locked |
Innovative foot care solutions are provided by Siren.
|
|
| Locked | Locked | Locked |
Silk-derived biomaterials are developed for soft tissue repair in surgery.
|
|
| Locked | Locked | Locked |
Regenerative biologic therapies for eye care are developed and provided.
|
|
| Locked | Locked | Locked |
Developer of regenerative materials
|
Detailed competitors of Reapplix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Reapplix
Complete news archive for Reapplix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Reapplix
Reapplix was founded in 2008.
Reapplix is headquartered in Rudersdal, Denmark.
Kira Rupprecht is the current CEO of Reapplix.
Reapplix is a funded company, having raised a total of $52.36M across 9 funding rounds to date.
As of Feb 29, 2024, the latest employee count at Reapplix is 10.
Annual revenue of Reapplix is $255.86K as on Dec 31, 2021.
Developer of patch system for wound healing. The company has developed a 3C Patch System that is used to separate, coagulate and pack it into a solid patch consisting of proteins, active cells, and growth factors. The solid patch is applied to the wounds where the patients own growth factors and stem cells are used to heal the wound and diabetic foot ulcers.
Reapplix's top competitors include Organogenesis, Siren and GeniPhys.
Reapplix offers 3C Patch System.
Reapplix has 9 investors. Key investors include Accelerace, Novo Holdings, Danmarks Eksport- og Investeringsfond, SEED Capital, and North-East.
The valuation of Reapplix is $41.5M as of Jul 2020.